Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Short Interest Update

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) saw a significant growth in short interest during the month of October. As of October 31st, there was short interest totalling 66,800 shares, a growth of 83.0% from the October 15th total of 36,500 shares. Based on an average daily volume of 1,140,000 shares, the short-interest ratio is presently 0.1 days. Currently, 3.3% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Roth Capital downgraded shares of Cyclacel Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. StockNews.com initiated coverage on shares of Cyclacel Pharmaceuticals in a report on Thursday, November 7th. They issued a “sell” rating on the stock.

Cyclacel Pharmaceuticals Trading Up 9.8 %

Shares of NASDAQ:CYCC traded up $0.04 on Wednesday, hitting $0.45. The company had a trading volume of 12,646,777 shares, compared to its average volume of 712,241. Cyclacel Pharmaceuticals has a 1-year low of $0.37 and a 1-year high of $7.84. The stock has a market cap of $967,500.00, a price-to-earnings ratio of -0.05 and a beta of 0.56. The stock has a 50 day moving average price of $0.88 and a 200 day moving average price of $1.44.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.36. The company had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.01 million. Cyclacel Pharmaceuticals had a negative net margin of 18,150.00% and a negative return on equity of 1,901.11%. Sell-side analysts anticipate that Cyclacel Pharmaceuticals will post -2.29 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Cyclacel Pharmaceuticals

An institutional investor recently bought a new position in Cyclacel Pharmaceuticals stock. Armistice Capital LLC bought a new stake in Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm bought 134,000 shares of the biotechnology company’s stock, valued at approximately $217,000. Armistice Capital LLC owned approximately 9.18% of Cyclacel Pharmaceuticals as of its most recent filing with the SEC. Institutional investors and hedge funds own 23.58% of the company’s stock.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.